Thymosin Beta-4 vs Teduglutide
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: TB-4, Tβ4
Thymosin beta-4 (Tbeta4) is a small 43 amino acid peptide found in nearly every cell in the body, originally isolated from the thymus. Its main job is binding and sequestering G-actin, the building block of the cell's internal scaffolding, which lets it influence cell movement, wound repair, and tissue regeneration. It is researched heavily for healing of skin, cornea, and heart tissue, but it is not an FDA-approved drug. (The injectable sold as TB-500 is a synthetic fragment marketed as related to Tbeta4, not the full natural peptide.)
Also: Gattex, Revestive
Teduglutide is a 33-amino-acid GLP-2 analog approved for short bowel syndrome (SBS) in people who depend on IV nutrition or fluids. GLP-2 is the gut's own growth signal, and teduglutide makes the remaining intestine grow taller villi and absorb more, so some patients can cut back the hours they spend hooked to a drip. The FDA approved it as Gattex in December 2012 (children 1 year and older were added in 2019), and in Europe it is sold as Revestive. It works, but it is a serious daily injection with real monitoring requirements, not a gut-health supplement.
Key Comparison Insights
- Teduglutide is FDA approved, while Thymosin Beta-4 remains in research stages.
- Both peptides belong to the Healing category, suggesting similar primary applications.
- Teduglutide has stronger research evidence (FDA Approved) compared to Thymosin Beta-4 (Human Trials).
Detailed Comparison
| Attribute | Thymosin Beta-4 | Teduglutide |
|---|---|---|
| Category | Healing | Healing |
| FDA Status | Not FDA Approved | FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Tbeta4's core action is binding monomeric G-actin, which regulates how cells assemble and disassemble their cytoskeleton and therefore how they migrate. By controlling actin dynamics it promotes cell migration into wounds, encourages new blood vessel growth (angiogenesis), and dampens inflammation. In injured tissue it acts as a chemoattractant, pulling in cells like endothelial cells, keratinocytes, and stem or progenitor cells to rebuild damaged areas. In the heart specifically, research suggests it can reactivate the epicardium, the heart's outer layer, and support survival of cardiac cells under low-oxygen stress. These are well-supported molecular actions, though translating them into proven clinical treatments is a separate question. | Teduglutide differs from natural GLP-2 by one amino acid (glycine swapped in at position 2), which shields it from DPP-4 breakdown and stretches its half-life from minutes to roughly 2 hours in healthy people (1.3 hours in SBS). It binds GLP-2 receptors on cells in the intestinal wall, which release local growth factors that increase villus height and crypt depth, improve blood flow to the gut, and slow gastric emptying and secretions. Net result: more absorptive surface and more time to absorb. The same growth signal is the reason for its main safety concern, because it can also speed the growth of polyps or existing tumors in the gut, so the label requires colonoscopy before and during treatment. |
| Common Dosing | 2.5-5 mg 2-3x weekly 2-3x weekly | 0.05 mg/kg once daily (labeled dose) Once daily |
| Administration | Subcutaneous injection, topical for eye conditions | Subcutaneous injection, rotating between abdominal quadrants, thighs, or arms |
| Typical Duration | 4-8 weeks typical protocol | Long-term, with assessment of benefit and ongoing monitoring; IV support is weaned as absorption improves |
| Best Time to Take | Morning or split doses | Same time each day, any time of day |
Possible Side Effects May vary by individual |
|
|
| Research Summary | There is genuine peer-reviewed research here, but the human evidence is concentrated in one area: the eye. The ophthalmic formulation RGN-259 (0.1% Tbeta4 eye drops) went through randomized placebo-controlled trials for dry eye and neurotrophic keratopathy, with a phase 2/3 dry eye trial in 317 patients showing significant improvement in corneal staining and ocular discomfort versus vehicle, published in peer-reviewed journals. For the heart, most evidence is preclinical: animal and large-animal studies, including a porcine myocardial infarction model, show Tbeta4 can improve cell engraftment, reduce infarct size, and aid recovery, but a major human cardiac trial program did not deliver an approved drug. Wound healing and hair growth effects are documented mainly in rodents. Across the board, Tbeta4 has a solid molecular story and promising preclinical data, but outside the eye program there are no completed pivotal human trials proving systemic benefit. The widely sold TB-500 research peptide has essentially no controlled human trial data of its own. | In the pivotal adult trial (Study 1, NCT00798967), 86 adults with SBS were randomized to teduglutide 0.05 mg/kg daily or placebo for 24 weeks. 63% on teduglutide versus 30% on placebo were responders (at least a 20% cut in weekly IV support at weeks 20 and 24), and weekly IV volume fell 4.4 L versus 2.3 L. In the 2-year open-label extension, 93% of the 30 patients who completed 30 months reached at least a 20% reduction, and a minority came off IV support entirely. An earlier trial (Study 3) used a different primary endpoint that missed at the higher dose, though responder rates at 0.05 mg/kg were 46% versus 6%. A 24-week pediatric study of 59 children aged 1 to 17 led to the 2019 approval: 69% on 0.05 mg/kg cut IV support by at least 20%, and 3 of 26 weaned off. Honest caveats: it is a lifelong therapy for most, benefits fade if stopped, and colon-in-continuity patients often respond less dramatically than those with a stoma. Longer-acting GLP-2 drugs (glepaglutide, apraglutide) are trying to replace the daily shot. |
Frequently Asked Questions: Thymosin Beta-4 vs Teduglutide
What is the difference between Thymosin Beta-4 and Teduglutide?
Thymosin Beta-4 is a healing peptide that thymosin beta-4 (tbeta4) is a small 43 amino acid peptide found in nearly every cell in the body, originally isolated from the thymus. its main job is binding and sequestering g-actin, the building block of the cell's internal scaffolding, which lets it influence cell movement, wound repair, and tissue regeneration. it is researched heavily for healing of skin, cornea, and heart tissue, but it is not an fda-approved drug. (the injectable sold as tb-500 is a synthetic fragment marketed as related to tbeta4, not the full natural peptide.) Teduglutide is a healing peptide that teduglutide is a 33-amino-acid glp-2 analog approved for short bowel syndrome (sbs) in people who depend on iv nutrition or fluids. glp-2 is the gut's own growth signal, and teduglutide makes the remaining intestine grow taller villi and absorb more, so some patients can cut back the hours they spend hooked to a drip. the fda approved it as gattex in december 2012 (children 1 year and older were added in 2019), and in europe it is sold as revestive. it works, but it is a serious daily injection with real monitoring requirements, not a gut-health supplement. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Thymosin Beta-4 or Teduglutide?
Neither is universally "better" - the choice depends on your specific goals. Thymosin Beta-4 is typically used for healing purposes, while Teduglutide is used for healing. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Thymosin Beta-4 and Teduglutide be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Thymosin Beta-4 and Teduglutide together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.